Ted Raad

Pulmatrix Inc (NASDAQ:PULM) Will Receive An Upfront Payment Of $7.2 Million From Johnson & Johnson (NYSE:JNJ)’s Lung Cancer Initiative For Licensing Kinase Inhibitor

Johnson & Johnson (NYSE:JNJ)’s Lung Cancer Initiative has signed a licensing and development accord to access narrow-spectrum Kinase inhibitors of Pulmatrix Inc (NASDAQ:PULM). As per the terms of the deal, Lung Cancer Initiative will initially pay an upfront amount of $7.2 million to Pulmatrix. The company will pay an additional amount of $2 million on […]